PET imaging of norepinephrine transporter - Expressing tumors using 76Br-meta-bromobenzylguanidine

Journal of Nuclear Medicine

Volumn 51, Issue 9, 2010, Pages 1472-1479

  Watanabe, Shigeki ^a   Hanaoka, Hirofumi ^b   Liang, Ji Xin ^a   Iida, Yasuhiko ^b   Endo, Keigo ^b   Ishioka, Noriko S ^a  

^a JAPAN ATOMIC ENERGY AGENCY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

123 131I MIBG; 76Br meta bromobenzylguanidine (76Br MBBG); Norepinephrine transporter (NET) expressing tumor; PET

Indexed keywords

(3 IODOBENZYL)GUANIDINE; FLUORODEOXYGLUCOSE F 18; META BROMOBENZYLGUANIDINE BR 76; NORADRENALIN TRANSPORTER; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG; 3 BROMOBENZYLGUANIDINE; 3-BROMOBENZYLGUANIDINE; ADRENERGIC RECEPTOR; BROMOBENZENE; DIAGNOSTIC AGENT; GUANIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; DEHALOGENATION; DRUG DISTRIBUTION; DRUG SCREENING; DRUG STABILITY; DRUG UPTAKE; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMAGING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR; ANIMAL; CELL STRAIN; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; RAT; SCINTISCANNING; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BROMOBENZENES; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANIDINES; MICE; NEOPLASMS; PC12 CELLS; POSITRON-EMISSION TOMOGRAPHY; RATS; RECEPTORS, ADRENERGIC;

EID: 77957094063     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.075465     Document Type: Article

References (36)

1. 131I]iodobenzylguanidine. J Nucl Med. 1980;21:349-353.
2. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.
3. Rufini V, Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging. 2008;52: 341-350.
4. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14:569-585.
5. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2008; 35:725-733.
6. 131I- metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer. 2008;98:1053-1058.
7. 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50:1237-1243.
8. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. Radiology. 1999; 212:35-41.
9. 18F-labelled deoxyglucose. Eur J Surg. 2001;167:866-870.
10. Ezuddin S, Fragkaki C. MIBG and FDG PET findings in a patient with malignant pheochromocytoma: a significant discrepancy. Clin Nucl Med. 2005; 30:579-581.
11. 123I-MIBG scintigraphy. Ann Nucl Med. 2008;22:395-401.
12. Rowland DJ, McCarthy TJ, Welch MJ. Radiobromine for imaging and therapy. In: WelchMJ, Redvanly CS, eds. Handbook of Radiopharmaceuticals: Radiochemistry and Applications. West Sussex, U.K.: John Wiley & Sons; 2003:441-465.
13. 76Br]MBBG). Nucl Med Biol. 1994;21:49-55.
14. Valette H, Loc'h C, Mardon K, et al. Bromine-76-metabromobenzylguanidine: a PET radiotracer for mapping sympathetic nerves of the heart. J Nucl Med. 1993; 34:1739-1744.
15. Clerc J, Mardon K, Galons H, et al. Assessing intratumor distribution and uptake with MBBG versus MIBG imaging and targeting xenografted PC12-pheochromocytoma cell line. J Nucl Med. 1995;36:859-866.
16. 76Br by a low-energy cyclotron. Appl Radiat Isot. 1998;49:1537-1540.
17. Nanni C, Leo DK, Tonelli R, et al. FDG small animal PET permits early detection of malignant cells in a xenograft murine model. Eur J Nucl Med Mol Imaging. 2007;34:755-762.
18. Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol. 2005;16:23-32.
19. 76Br-bromide and PET. J Nucl Med. 2003;44:1210-1218.
20. Gudjonssona O, Bergstrom M, Kristjansson S, et al. Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. Nucl Med Biol. 2001;28:59-65. (Pubitemid 32155965)
21. Berry CR, Garg PK, DeGrado TR, et al. Para-[18F]fluorobenzylguanidine kinetics in a canine coronary artery occlusion model. J Nucl Cardiol. 1996;3:119-129.
22. 18F]fluorobenzylguanidine. Nucl Med Biol. 1994;21:97-103.
23. 11C]guanidine. J Labelled Comp Radiopharm. 1997;39:525-529.
24. Vaidyanathan G, Affleck DJ, Zalutsky MR. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med. 1995;36:644-650.
25. Moroz MA, Serganova I, Zanzonico P, et al. Imaging hNET reporter gene expression with I-124-MIBG. J Nucl Med. 2007;48:827-836.
26. Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for I-131 metaiodobenzylguanidine radiotherapy of neural crest tumors using I-124 metaiodobenzylguanidine positron emission tomography. Br J Radiol. 1992;65: 787-791.
27. 18F DOPA whole body PET-initial results. Radiology. 2002;222:507-512.
28. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. J Nucl Med. 2009;50:513-519.
29. 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf). 2008;69:580-586.
30. 111In-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma. J Nucl Med. 2008;49:1613-1619.
31. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004; 89:479-491.
32. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083-4087.
33. 18F] fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension. 2001;38:6-8.
34. Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998;25:79-83.
35. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab. 2007;92: 1217-1225. (Pubitemid 46556388)
36. 131I] metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol. 2009;27:4162-4168.